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Introduction
Gastric carcinogenesis is a complex, multistep and 
multifactorial process, which the majority of cases are 
thought to be caused by environmental factors that cause 
damage in the mucosa and inhibit its capability to repair 
itself. This response is controlled, partly, by regulatory 
factors that are produced with proto-oncogenes and tumor 
suppressor genes (Tahara, 1993; Oh et al., 2014). In Iran, 
the most common deadly cancer is gastric adenocarcinoma, 
which has a wide variation of death rate in southern Iran 
3.6 per 100,000 per year as compared to a rate of 8.4 per 
100,000 in East Azerbaijan, northern Iran (Fallah, 2007; 
Atrkar-Roushan et al., 2013; Somi et al., 2014).
The p53 protein, was known as ‘the guardian of the 
genome’, and is an important regulator of cellular growth 
control (Harris and Hollstein, 1993). Clinical studies and 
mouse models have shown that p53 is mutated in 50% 
of human cancers, and functionally inactivated in much 
more (Marine et al., 2006). More than 200 SNPs (germline 
variants) have been recognized in p53; in contrast to 
tumor-associated mutations, most of these p53 SNPs 
have, improbably, biological effects. Based on the key 
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Abstract
 Background: Development of gastric cancer (GC) is a multistep process that requires alterations in the 
expression of oncogenes and tumor suppressor genes, occurring over several decades. The p53 tumor suppressor 
protein is involved in cell-cycle control, apoptosis and DNA repair. One of the most important regulators of p53 
is MDM2, which acts as a negative regulator in the p53 pathway. Based on the key role of p53 and MDM2 in 
tumor suppression, polymorphisms that cause change in their function might affect cancer risk. We therefore 
elevated associations of the polymorphisms of p53 (R72P) and MDM2 (SNP309) with GC in Iran. Materials and 
Methods: A total of 104 patients with gastric cancer and 100 controls were recruited. Genomic DNA was extracted 
from fresh gastric samples. Genotyping of the p53 and MDM2 genes was performed using allele specific PCR 
(AS-PCR). Results: There was no significant difference between the p53 codon 72 polymorphism distribution 
in control and patient groups (p=0.54), but the G allele of MDM2 was found to be over-represented in patients 
(p=0. 01, Odds Ratio=2. 08, 95% Confidence Interval= 1.37-4.34). Conclusions: The p53 R72P seems not to be a 
potential risk factor for development of GC among Iranian patients, but our data suggest that MDM2 SNP309 
might modify the risk related to GC. 
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role of p53 in tumor suppression, the polymorphisms that 
cause changes in p53 function might affect cancer risk, 
progression and/or response to treatment (Whibley et al., 
2009). The p53 codon 72 polymorphism (p53 R72P) alter, 
non-conservatively, an arginine (R72) to a proline (P72) 
at amino acid 72 that causes structural changes of the 
protein giving rise to variants of separate electrophoretic 
mobility (Harris et al., 1986; Matlashewski et al., 1987). 
This SNP takes place in a proline-rich region of p53, 
which is pivotal for the apoptotic functions of this protein 
(Walker and Levine, 1996; Sakamuro et al., 1997). One 
of the pivotal points of the p53 pathway is the MDM2 
protein (Bond et al., 2005a). MDM2 (murine double 
minute 2) was discovered on double minute chromosomes 
in a derived cell line of NIH-3T3 cells (Fakharzadeh et 
al., 1991; Momand et al., 1992). MDM2, as a p53 target 
gene, is part of E3 ubiquitin ligases family that includes 
a RING [really interesting new gene] domain and for p53 
degradation act as the major E3 ubiquitin ligase (Pei et al., 
2012). The MDM2 protein binds to p53 and regulates that 
by changing its location, stability and activity(Poyurovsky 
and Prives, 2006). Consistent with MDM2 role as a 
negative regulator of p53, altering its levels has been 
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shown in many mouse models to affect p53-dependent 
tumor suppression (Poyurovsky and Prives, 2006). MDM2 
level is crucial for p53 tumor suppression, and even a 
moderate change in MDM2 levels could affect cancer in 
mice and a naturally occurring sequence variation in the 
MDM2 promoter/enhancer region brings about modifying 
expression of the MDM2 protein, and affects p53 tumor 
suppression and ,eventually, causes cancer (Bond et al., 
2004). Upon Bond et al. report, SNP 309 (rs2279744, 
T>G) downstream from MDM2 intron 1, cause disruption 
of Sp1 regulatory element and formation of the T allele, 
therefore, has a conspicuously lower promoter activity 
in comparison with the G allele (Bond et al., 2004; Tian 
et al., 2013).
The present study aimed to examine the association 
between p53 and MDM2 polymorphisms and gastric 
cancer risk.
Materials and Methods
Participants
Gastric biopsies were obtained from 104 people 
with a diagnosis of gastric cancer and 100 cancer-free 
controls matched for age and sex were also evaluated. 
GC patients were recruited between May 2011 and June 
2012. All registered subjects underwent endoscopy, and 
endoscopic findings were reviewed by two experienced 
endoscopists. The specimens were immediately frozen and 
stored at -70°C until DNA extraction. Informed consent 
was obtained from all participants and ethical principles 
of the Helsinki Declaration were followed.
Genomic DNA extraction
Genomic DNA was extracted from endoscopic 
biopsy specimens. Tissue samples were suspended in 
500 µl of extraction buffer containing 2 mM EDTA, 400 
mM NaCl and 10 mM Tris-HCl (pH 8.0). The mixture 
was incubated at room temperature for 20 min. The 
solution was incubated at 55ºC overnight, after addition 
of Proteinase K and sodium dodecyl sulfate (400 ng and 
0.6%, respectively). DNA extraction was done by GPP 
solution kit (Gen Pajoohan, Iran) as previously described. 
(Moradi et al., 2013) Extracted DNA was observed 
and confirmed by electrophoresis on 0.1% agarose gel 
containing etidium bromide. The concentration and purity 
of DNA were assessed with a Nanodrop (Thermo) with 
260/280 measurement ratio and at the wavelength of 260 
and 280 nm. Extracted DNA was stored at -70°C until use.
Polymorphism analysis
For genotyping of the P53 and MDM2  AS-
PCR were used. For p53 R72P genotyping, two 
independent polymerase chain reaction (PCR) assays 
for each allele were used. Genomic DNA amplified 
by PCR using primers that detect p53 codon 72 in the 
proline form (5’-GCCAGAGGCTGCTCCCCC-3’; 
5’ CGTGCAAGTCACAGACTT-3’) and arginine 
f o r m  ( 5 ’ T C C C C C T T G C C G T C C C A A - 3 ’ ; 
5’-CTGGTGCAGGGGCCACGC-3’) according to the 
procedure described by Storey et al. (1998). (Storey et 
al., 1998)
MDM2 SNP309 (rs2279744, T>G) genotypes were 
analyzed using two independent PCR assays for each 
allele, modified from a technique described by Menin 
et al. (2006) (Menin et al., 2006). The procedure was 
performed using primer pairs specific for the two alleles. 
Primers F1 (5’-GGATTTCGGACGGCTCTC-3’) and 
R1 (5’-TCCGGACCTCCCGCGCCGA-3’) were used 
to amplify the 121-bp wild-type allele (T), and primers 
F2 (5’-GTTTTGTTGGACTGGGGCTA-3’) and R2 
(5’-ATCCGGACCTCCCGCGCCGC-3’) were used to 
amplify the 168-bp mutant allele (G). 
The amplification procedure was carried in a total 
reaction volume of 25 μl, containing 2.5 μl 10X PCR 
buffer, 2 μl deoxy ribonucleotide triphosphates (1.25 
μmol/L), 0.5 μl MgCl2 (25 mmol/L), 1.25 μl of each 
primer (25 mmol/L), 15.3 μl dH2O, 2 μl DNA (100 ng/μl) 
and 0.2 μl Taq DNA polymerase (5 U/μl) (Biflux, Japan).
After an initial denaturation at 94°C for 3 min, the 
DNA was amplified by 35 cycles of 94°C for 30 Sec, 60°C 
for 30s and 72°C for 30s, with a final extraction at 72°C 
for 5 min on the Mini PCR (Bio-Rad), then the products 
electrophoresed on a 2% agarose gel, to allow detection 
by ethidium bromide staining. All assays were conducted 
blindly by two researchers without the knowledge of the 
case or control status. For quality control, a random of 5% 
of samples was repeated with 100% concordance.
Statistical analysis
All statistical analyses were performed using MedCalc 
statistical software (Version 12.1, Mariakerke, Belgium). 
Differences in genetic distributions between patients and 
the controls were calculated by Pearson’s chi-square 
(χ2) test. Odds ratios (OR) and 95% confidence intervals 
(95%CI) were estimated using an unconditional logistic 
regression model. The results were considered statistically 
significant when p<0.05.
Results 
This study included 104 patients with gastric cancer 
(44 in females and 60 in males) and 100 cancer-free 
control subjects (38 in female and 62 in males) (Table 1). 
There were no statistically significant differences in the 
distributions of sex and age between patients and controls 
(p>0.05). The length of PCR products for p53 codon 72 
Pro and Arg alleles was 177 and 141 bp, respectively 
(Figure 1). The frequencies of p53 R72P genotypes have 
been estimated using an allele specific PCR (AS-PCR) 
that specifically detects either the p53 proline or arginine 
allele for codon 72. The allelic frequencies in the patient 
group were Arg 48% and Pro 52%; however, the difference 
did not reach statistical significance using odds ratio test 
(p=0.25). The distribution of genotypes and polymorphic 
alleles in patients and controls are summarized in Table 
2. No significant difference was observed regarding the 
P53 genotype frequencies at codon 72 between patients. 
Among the 104 Gastric cancer patients, 6 (5.7%) Arg 
homozygotes, 10 (9.7%) Pro homozygotes and 88 (84.6%) 
Arg/Pro heterozygotes were identified. From the controls 
27 (27%) were Arg homozygotes, 15 (15%) Were Pro 
homozygotes and 58 (58%) were heterozygous. The 
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homozygous genotype frequencies were 16 (15.4%) in 
cancer cases and 42 (42%) in control subjects.
AS-PCR was also used for genotyping MDM2 
SNP309, which products have 168 bp (G allele) and 
121 bp (T allele) in length (Figure 2). The G allele was 
significantly associated with the presence of gastric cancer 
(p=0.01). The frequency of GG, TG and TT genotypes of 
MDM2 SNP309 polymorphism in the controls was 4%, 
66% and 30%, respectively, while those in gastric cancer 
patients were 17.3%, 75% and 7.7% (Table 2).
Discussion
The p53 tumor suppressor protein is a classic 
gatekeeper of cellular fate (Ko and Prives, 1996; 
Vogelstein et al., 2000). Although loss of p53 function 
causes tumor susceptibility, hyperactivation of p53 is 
lethal; therefore, p53 activity must be severely regulated 
for normal tissue homeostasis maintenance (Wade et al., 
2010). MDM2 is a crucial negative regulator of p53, that 
promote its degradation, as disclosed by models in which 
deletion of MDM2 gene is lethal in a p53-dependent 
manner (Marine et al., 2006; Ren et al., 2013).
Several epidemiological studies have evaluated the 
connection of p53 R72P, MDM2 SNP309 and risk of 
different types of cancer (Marine et al., 2006; Sadeghi 
et al., 2013; Song et al., 2013). In the current study the 
p53 R72P and MDM2 SNP309 polymorphisms were 
investigated in a series of 104 patients of GC, and in 
100 population matched controls in order to verify the 
impact of P53 and MDM2 variants on the risk of tumor 
development in Iranian GC patients. 
Our results showed no significant differences in the 
genotype distribution of the p53 R72P polymorphism 
between patients and controls, and trivial increase in 
the frequency of the proline alleles among patients and 
the arginine allele among controls was not significant. 
This observation is in agreement with previous study 
reporting no association between p53 R72P polymorphism 
and GC cancer in a group of 224 Iranian patients 
with gastrointestinal cancers (92 with GC and 132 
with colorectal cancer) and in 163 healthy controls 
(Mojtahedi et al., 2010). Hamajima and coworkers found 
no association between the Pro allele and the risk of 
gastrointestinal cancer in Japanese patients (Hamajima et 
al., 2002). Conversely, a moderate increase in the risks of 
gastric cancer and colorectal cancer with higher frequency 
of Pro/Pro genotype was observed among Korean patients 
(Wo et al., 2011), and also the association between p53 
R72P and GC observed among Chinese Han patients, 
was significant  (Zhou et al., 2010). 2012 updated meta-
analysis about the association of the p53 R72P and GC 
risk was done among twenty-eight studies, 16 of them 
were conducted in an Asian population (5,617 cases and 
6,347 controls), 11 in a Caucasian population (1,158 
cases and 2,745 controls) and one in a mixed population 
(84 cases and 185 controls). This study indicated that 
the p53 codon 72 Arg/Arg genotype is associated with 
a moderately decreased risk of GC in Asians (OR=0.87, 
95%CI=0.78-0.97, p=0.01), and those differences in 
genotype distribution may be associated with cancer 
stage, location, differentiation and metastasis. Although, 
among Caucasians no significant difference in genotype 
distribution (Arg/Arg: OR=1.03, 95%CI=0.85-1.26; Arg/
Pro: OR=1.03, 95%CI=0.80-1.32; Pro/Pro: OR=0.88, 
95%CI=0.64-1.21) was observed, suggesting that the 
p53 R72P may have no significant influence on the GC 
risk in Caucasian populations. This may be as a result 
Table 2. Distribution of TP53 Codon 72 and MDM2 
SNP309 Genotypes in GC Cases and Controls 
 GC Cases  Controls  ORa  p valueb
 (n=104) n (%) (n=100) n (%) (95%CI)
p53P72R
 Pro allele 108 (52) 88 (44) 1 (Ref) 
 Arg allele 100 (48) 112 (56) 1.37 (0.79-2.4) 0.25
 P/P 10   (9.7) 15 (15) 0.37 (0.11-1.2) 0.1
 P/R 88 (84.6) 58 (58) 0.15 (0.05-0.39) 0.001
 R/R 6   (5.7) 27 (27) 0.29 (0.06-1.4) 0.12
 R/R+P/R  94 (90.4) 85 (85) 1.404(0.47-4.18) 0.54
MDM2SNP309
 T allele 47 (45) 126 (63) 1 (Ref) 
 G allele 57 (55) 74 (37) 2.08 (1.37-4.34) 0.01
 T/T 8   (7.7) 30 (30) 1 (Ref) 
 T/G 78 (75) 66 (66) 4.43 (1.33-14.66) 0.01
 G/G 18 (17.3) 4   (4) 16.87 (2.55-111) 0.003
 G/G+T/G 96 (92.3) 70 (70) 5.00 (1.5-16.8) 0.006
Figure 2. MDM2 SNP309 PCR Product Stained by 
Ethidium Bromide on 2% Agarose Gel-Electrophoresis. 
T/T homozygote had a single band of 121 bp (lane 1). T/G 
heterozygote had two bands of 121 and 168 bp (lane 2) and G/G 
homozygote had a single fragment of 168 bp (lane 3) 0
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Table 1. Characteristics of Gastric Cancer Patients 
and Cancer-free Controls
Variable  Patient Healthy control
  (n=104) n (%) (n=100) n (%)
Mean age, years (±SDa) 67.8 (±8.84) 64.2 (±5.14)
Age, years <50 2   (1.93) 16 (16)
 50-65 22 (21.15) 66 (66)
 >65 80 (76.92) 18 (18)
 Males 60 (57.7) 62 (62)
 Females 44 (42.3) 38 (38)
*SD: Standard diviation
Figure 1. p53 R72P PCR Products Stained by Ethidium 
Bromide on 2% Agarose Gel Electrophoresis. Lanes: 
(M), 50- bp DNA marker; (1-3), 141-bp and (3-6), 177-bp 
fragments amplified from different samples
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of the significant difference in the distribution of this 
polymorphism between races (Liu et al., 2012).
To our knowledge, no study has been published about 
the association of MDM2 SNP309 polymorphism with GC 
in Iranian population per se. The frequencies of MDM2 
SNP309 G/G homozygous (17.3%) and T/G heterozygous 
(75%) genotypes were significantly higher among GC 
patients in comparison to controls (p=0.003 and p=0.01, 
respectively). The MDM2 SNP309 T/T homozygous 
genotype in GC was lower (7.7%) than that observed in 
controls (30%).
There are some reports assessing the MDM2 SNP309 
in gastric cancer. In a case-control study including 438 
controls and 410 patients with sporadic gastric carcinoma, 
MDM2 SNP309 genotyping showed significant association 
between SNP309 with gastric carcinogenesis. The risk 
of overall gastric carcinoma for SNP309 (G/G) was 
significantly increased when compared with T carriers 
(p=0.039) (Ohmiya et al., 2006).
A meta-analysis of MDM2 SNP309 and tumor 
vulnerability indicated that MDM2 SNP309 is a plausible 
tumor biomarker. The reviewed data indicated that variant 
homozygote 309GG and heterozygote 309TG were 
associated with a significant increased risk of most tumor 
types (homozygote comparison: odds ratio (OR)=1.25, 
95% confidence interval (CI)=1.13-1.37; heterozygote 
comparison: OR=1.10, 95%CI=1.03-1.17) (Wo et al., 
2011).
The p53 could be activated in cellular stresses, and 
MDM2 SNP309 can act as a key mediator upon this 
response. For instance, 5- to 14-fold raises in p53 protein 
level occur in SNP309 TT cells upon the stress signals; 
whereas only 2- to 3-fold raises occur in SNP309 GG 
cells (Bond et al., 2005b). Another study indicated that 
MDM2 targets p53 for degradation only in stressed GG 
cells, and in non-stressed cells, increased levels of MDM2 
do not further decrease the levels of wide-type p53 protein 
(Bond et al., 2004). 
In conclusion, these results provide the first evidence 
from Iran that showed the MDM2 SNP309 polymorphism 
is a risk factor for gastric cancer. Conversely, the p53 R72P 
seems not to be a potential risk factor for development 
of GC among the Iranian population. Since genetic 
polymorphisms often vary among different ethnic groups, 
the different results in different populations may be due 
to different genetic background. 
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